I mmunological memory, adapting from a primary immune response to a given Ag, is the central basis of vaccination. In a T cell-dependent immune response, T follicular helper (Tfh) cells that encounter Ag-primed B cells in the secondary lymphoid organs provide cytokines, such as IL-21, and costimulatory interaction including CD40L to support Ag-primed germinal center (GC) B cells. This process instructs the differentiation of either memory B cells or Ab-secreting plasma cells (1, 2) . Preceding the differentiation to form memory B or plasma cells, GC B cells undergo somatic hypermutation of Ig variable regions to acquire the enhanced ability to recognize Ags. The molecular bases involved in deciding the specification of GC B cells to differentiate into memory B cells or plasma cells are largely unknown. The gene-regulatory networks controlling the generation of plasma cells have been demonstrated. The induction of B lymphocyteinduced maturation protein-1 (Blimp-1), encoded by PRDM1, in Ag-primed B cells is essential for plasma cell fate (3, 4) . IFN regulatory factor 4 is important for the initiation of plasma cell differentiation and Blimp-1 induction (5, 6) . Other mechanisms leading to the induction of Blimp-1 during the differentiation plasma cells include the downregulation of mature B or GC B cell genes, Pax5, and Bcl6 (6, 7). Downregulation of Pax5 permits the induction of Xbp-1 that is crucial for the secretion of Ab (8, 9) . However, the transcription factors pivotal for the establishment of memory B cell fate are not known.
A previous microarray study showed that Blimp-1 drives plasma cell differentiation by repressing genes that are involved in B cell identity and GC B cell function (10) . One of the genes revealed by that study encodes basic helix-loop-helix transcription factor activated B cell factor-1 (ABF-1). Transcription factor E proteins have many important functions during immune cell development/ differentiation, especially in lymphocytes (11) . There are four E proteins in mammals: E12, E47 (both encoded by E2A), HEB, and E2-2 (11) (12) (13) . ABF-1, also known as musculin (MSC), was discovered with a yeast two-hybrid screen of a B cell cDNA library using the bHLH region of E2-2 as bait (14) . ABF-1 binds to the Ebox element to form a homodimer or heterodimer with E12 or E47 (14) . The transcriptional activity of E47 is attenuated by the repression domain located in the C-terminal half of ABF-1 (14, 15) . ABF-1 is expressed in human lymphoid tissues including lymph nodes, fetal liver, and bone marrow, EBV-transformed lymphoblastoid cell lines, and activated human B cells (14) . The physiological function of ABF-1 in human B lymphocytes has not been determined. High expression of ABF-1 and Id2 in classical Hodgkin lymphomas inhibits E2A activity, which causes the loss of expression of B cell-associated genes and upregulation of aberrant genes such as TCF7 and CSF1R that are not normally expressed in the B cell lineages (16) . The mouse homolog of ABF-1, MyoR (myogenic repressor), or Msc, is predominantly expressed in undifferentiated, proliferating myoblasts and is downregulated during differentiation (17, 18) ; whether it is involved in B cells is still unknown.
In this study, we sought to pursue the function of ABF-1 in the context of plasma cell differentiation and uncovered the role of *Genomics Research Center, Academia Sinica, Taipei 115, Taiwan; ABF-1 in the promotion of GC and memory B cell fate and the suppression of plasma cell formation.
Materials and Methods

Cell culture and reagents
Human B cells were purified first with a RosetteSep HLA B cell Enrichment Cocktail (StemCell Technologies) through negative selection followed by incubation with anti-CD27-coupled magnetic beads (Miltenyi Biotec) to isolate memory B (CD27 + ) cells. Naive B (CD27 2 ) cells were obtained from the flow-through fraction. Purified human B cells at a density of 1 3 10 6 cells/ml were stimulated with IL-21 (100 ng/ml; Invitrogen) and anti-CD40 (1 mg/ml; R&D Systems). SKW 6.4 (SKW) human lymphoblastoid cells, 18-81 pre-B cells, 293T cells, and 3T3 cells were maintained as described (10, 19) . Stable WI-L2 transfectants were maintained as described (10) , and Blimp-1-estrogen ligand-binding domain (ERD) was induced by 5 mM CdCl 2 (Sigma-Aldrich) and 3 mM 4-OHT (SigmaAldrich) treatment for 10 h. Mouse splenic B cells were purified by positive selection using B220 microbeads (Miltenyi Biotec), and the purified B cells were stimulated with LPS (2 mg/ml), goat anti-mouse F(ab9) 2 (10 mg/ml; Jackson ImmunoResearch Laboratories), anti-CD40 (1 mg/ml; BD Biosciences), and IL-21 (200 ng/ml; eBioscience) at a density of 1 to 2 3 10 6 /ml.
Plasmids
Details of plasmid information, including ABF-1 tagged with GFP at the C terminus (ABF-1-GFP), shRNA against ABF-1 and GFP-Blimp-1 expressed by a lentiviral vector, pFUGW (20) , are available upon request. The genomic fragment containing 22967 to +318 of ABF-1 was amplified from genomic DNA of primary human peripheral mononuclear cells and was cloned into pGL3 basic vector (Promega) to generate ABF-1-Luc. Details of the construction of various derivatives of ABF-1-Luc that carry mutated sequences by site-directed mutagenesis at the Blimp-1 binding sites are available upon request.
Generation of EmV H -ABF-1-estrogen receptor transgenic mice and immunization
To express ABF-1 in B cells in an inducible manner, we generated transgenic (TG) mice with ABF-1 cDNA fused in-frame to the N-terminal region of mouse estrogen receptor (ER) and then subcloned ABF-1-ER cDNA into pEmV H (provided by Dr. Suzanne Cory, Walter and Eliza Hall Institute), in which ABF-1-ER transcription was controlled by the IgM enhancer (Em) and a V H promoter (21) . The TG mice were produced by Level Biotechnology, Taiwan, and were maintained in C57BL/6 genetic background. Germline transmission of ABF-1-ER by TG founders and the subsequent confirmation of TG passages were conducted by PCR with primers spanning the fusion region of the cDNA sequences of ABF-1 and ER (primer sequences 59-CTCAGCCGCAGAGTGCAAGC-39 and 59-CTTCTCCCTGCAGGTTCATCA-39). All mice were maintained under specific pathogen-free conditions in the animal facility of the Institute of Cellular and Organismic Biology at Academia Sinica, and the animal experimental protocol was approved by the Institutional Animal Care and Utilization Committee at Academia Sinica. We induced ABF-1 activity in EmV H -ABF-1-ER TG mice by i.p. injection of 4-hydroxytamoxifen (4-OHT) (100 mg in 250 ml seed oil; Sigma-Aldrich) on every other day six to eight times. Littermate wild-type (WT) mice were used for comparison. TG or WT mice were immunized i.p. with 100 mg (4-hydroxy-3-nitrophenyl) acetyl (NP) 25 -keyhole limpet hemocyanin (KLH) (Biosearch Technologies) in the primary and secondary immunizations (6 wk apart).
In some experiments, two injections of BrdU (1 mg in 200 ml Dulbecco's PBS solution; BD Biosciences) were performed with a 6-h interval on day 6 after primary immunization. After 24 h, BrdU-incorporated B cells were analyzed by staining with the fluorescence-conjugated anti-BrdU followed by flow cytometric analysis. Adoptive transfer of splenocytes was performed according to a previous publication (22) . Briefly, CD138 + plasma cells in single-cell suspensions of splenocytes from immunized mice were magnetically labeled with CD138 Microbeads (Miltenyi Biotec) and then removed by a column. A total of 2 3 10 7 plasma cell-depleted splenocytes were transferred i.v. to unimmunized B6.SJL (CD45.1 + ) mice (Taconic Farms). Twenty-four hours later, mice were immunized with 100 mg NP-KLH in 200 ml PBS by i.p. injection.
RNA isolation and RT-quantitative PCR
Total RNA was isolated by RNeasy mini kit (Qiagen). cDNA synthesized by Sensiscript Reverse Transcriptase kit (Qiagen), and real-time quantitative PCR (QPCR) was performed according to a previous publication (19) . b 2 -microglobulin and Rpl32 mRNA were used for internal normalization for human and mouse samples, respectively. The b 2 -microglobulin, PRDM1-, ABF-1-, PAX5-, BCL6-, XBP-1-, Msc-, and Rpl32-specific TaqMan primer and probe sets were purchased from Applied Biosystems. The primer sequences used in SYBR Green method are listed in Supplemental Table I .
Immunoblotting
The immunoblotting procedure was performed essentially as in the previous report (19) . The primary Abs in immunoblotting are: mouse anti-Blimp-1 Ab (1:500 dilution) (19) , goat anti-Msc/ABF-1 Ab (1:200 dilution; Santa Cruz Biotechnology), mouse anti-tubulin Ab (1:5000 dilution; Thermo Fisher Scientific), rabbit anti-histone deacetylase 2 (1:1000 dilution; Santa Cruz Biotechnology), and mouse anti-lamin A/C Ab (1:1000 dilution; Santa Cruz Biotechnology). Immunoblotting results shown in this study are from a single experiment that is representative of at least three experiments.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) for detection of FLAG-Blimp-1-ERD binding in vivo using anti-FLAG Ab was performed, and the results were normalized as described in a previous report (19) . Regions encompassing or adjacent to Blimp-1 binding sites were amplified by QPCR. A region located at 24 kb of ABF-1 was amplified as a negative control site. Input DNA amplified by QPCR was used to normalize data for each individual site. The primer sequences used are listed in Supplemental Table I .1
DNA pulldown assay and EMSA
The DNA pulldown assay was performed essentially as described (23) . Recombinant truncated form of Blimp-1 (tBlimp) was expressed and purified according to a previous report (24) . The EMSA was performed with a LightShift chemiluminescence EMSA kit (Pierce) (23) . Briefly, 2 mg nuclear extract from 293T cells transfected with Blimp-1 expression vector was incubated with 45 fmol biotin-labeled probe in the absence or presence of the indicated excess amount of unlabeled oligonucleotides. In the supershift assay, 0.5 mg mouse anti-Blimp-1 Ab (23) or control mouse IgG (Sigma-Aldrich) was added to the reaction. The oligonucleotides corresponding to various Blimp-1 binding sites and the negative control oligonucleotides are listed in Supplemental Table I .
Transfection and luciferase reporter assay ABF-1-Luc (15 mg) or its various mutants, various amounts of Blimp-1 expression vector (pCMV-Blimp1) or control vector (pCMV-5b), and 0.3 ng Renilla luciferase reporter driven by the thymidine kinase promoter (RL-tk) were cotransfected into 18-81 B cells by electroporation at 230 V and 950 mF. After 18 h, cells were lysed and subjected to firefly luciferase and Renilla luciferase assays using the Dual-Luciferase Reporter Assay kit (Promega). The luminescence was measured by TopCount NXT (PerkinElmer). Fold repression was calculated as described (19) .
Generation of lentivirus and viral transduction
The procedure for preparing lentiviral vectors was performed as previously described (19) . 
ELISA and ELISPOT assays
Cell-culture supernatants were harvested for ELISA to determine the amount of IgM or IgG as described (9) . ELISPOT analysis for detecting IgG-secreting cells essentially followed a previously reported procedure (9) . NP-specific Ab titers in TG or WT mice were determined as described (3). NP 52 -BSA or NP 4 -BSA (1 mg/well; Biosearch Technologies) in PBS was used to coat MultiScreen HTS plates (Millipore), and the plates were later blocked with 2% skim milk in PBS.
Flow cytometry
The procedure for flow cytometric analysis was according to a previous report (19) . Abs used in flow cytometric analysis were purchased from BD Biosciences, unless otherwise mentioned, and they are: allophycocyanin-or PE/Cy7-conjugated anti-human CD38 (clone HB7), PE-conjugated antihuman IgD (clone IA6-2), PerCP-Cy5.5-conjugated anti-BrdU (clone 3D4), FITC-conjugated anti-mouse GL7 (clone GL7), allophycocyaninconjugated anti-mouse IgG 1 (clone X56), allophycocyanin-Cy7-conjugated anti-mouse B220 (clone RA3-6B2), PE-Cy7-or FITC-conjugated anti-mouse CD38 (clone 90; BioLegend), FITC-conjugated anti-mouse CD79b (clone HM79b), PerCP-Cy5.5-conjugated mouse Gr-1 (clone RB6-8c5), PE-Cy7-conjugated anti-mouse F4/80 (clone BM8, BioLegend), allophycocyaninconjugated anti-mouse CD138 (clone 281-2; BioLegend), allophycocyaninconjugated anti-mouse CD43 (clone S7), FITC-conjugated anti-mouse IgD (clone 11-26c.29; BioLegend), PerCP-Cy5.5-conjugated anti-mouse IgM (clone R6-60.2), PE-Cy7-conjugated anti-mouse CD23 (clone B3B4; BioLegend), allophycocyanin-conjugated anti-mouse CD21 (clone 7E9; BioLegend), PerCP-conjugated anti-CD45.2 (clone 104), and NP conjugated with PE (Biosearch Technologies). Apoptotic cells were detected by Annexin V-PE apoptosis detection kit I (BD Biosciences). Cells were analyzed by FACSCanto (BD Biosciences), and FCS Express 3.0 or FACSDiva software was used for data analysis. In some experiments, cells were sorted by FACSAria (BD Biosciences).
Immunohistochemistry
Two weeks after immunization, isolated mouse spleens were fixed by 10% formaldehyde and embedded in paraffin. Sections, sliced at 3-mm thickness, were dewaxed and incubated with retrieval solution (pH 9; DakoCytomation). After blocking with 3% human serum (Invitrogen), slides were incubated with biotinylated peanut agglutinin (PNA; 1:100; Vector Laboratories) at 4˚C overnight and then immersed in VECTAS-TAIN ABC (Vector Laboratories) followed by color development with diaminobenzidine staining. After washing with tap water, slides were incubated with anti-B220 (BD Pharmingen) at 4˚C overnight. Immunoreactive signals were visualized by incubation of anti-rat IgG conjugated with alkaline phosphatase (Vector Laboratories) followed by color development with nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate substrates (Roche). For quantification of GC B cells, spleen sections from three WT or ITG mice were analyzed. In each section, three GCs were randomly selected for counting PNA + cells in fixed area (80 3 50 mm).
Microarray
Three to five micrograms total RNA was used per cDNA microarray. The following procedures and data analysis were performed essentially as previously described (25) . The microarray dataset from this study is deposited at the National Center for Biotechnology Information Gene Expression Omnibus with accession number GSE26583 (http://www.ncbi. nlm.nih.gov/geo/).
Statistics
Statistical significance was analyzed by the paired t test for human samples or unpaired t test for mouse study. Data shown are the mean 6 SD or the mean 6 SEM as indicated. Significance of p values was as follows: *p , 0.05, **p , 0.005, ***p , 0.001.
Results
ABF-1 is predominantly expressed by memory B cells and altered expression of ABF-1 in memory B cells affects human plasma cell formation in vitro
Human blood B cells treated with IL-21 and anti-CD40, which mimics the help from Tfh cells, undergo extensive proliferation, class switching, and Ab secretion (26, 27) . Using this differentiation model, we examined the expression of ABF-1. As reported (27) , PRDM1 mRNA levels were induced (Fig. 1A) . We found that following stimulation with IL-21 and anti-CD40, ABF-1 mRNA levels declined by day 6 (Fig. 1B) . Given that human peripheral B cells consist of naive B cells and memory B cells, and they can be separated on the basis of the absence or presence of surface CD27 expression, respectively (28), we wondered if ABF-1 is expressed in particular subsets of B cells. PRDM1 mRNA was induced in both naive and memory B cell-derived cultures treated with IL-21 and anti-CD40 (Fig. 1C) . Notably, the basal levels of ABF-1 mRNA in freshly isolated memory B cells were significantly higher than the levels in naive B cells (Fig. 1C) ; the levels of ABF-1 mRNA in memory B cell-derived cultures increased on the first day and then declined thereafter (Fig. 1C) .
We then examined if ABF-1 is involved in the formation of Absecreting cells that were differentiated from human peripheral blood memory B cells. We found that reduced generation of IgD lo CD38
hi cells and decreased production of IgG were detected in stimulated memory B cell-derived cultures expressing ABF-1-GFP compared with those expressing GFP alone ( Fig. 1D-F) . Reversely, we assessed if knockdown of ABF-1 expression in human blood memory B cells with a lentiviral vector expressing short hairpin RNA (shRNA) against ABF-1 ( Fig. 1G) , affects the formation of Ab-secreting cells. Our results show that knockdown of ABF-1 led to increased frequency of CD38 hi cells (Fig. 1H ) and elevated numbers of IgG-secreting cells (Fig. 1I ) 3 d after stimulation. The effect of ABF-1 on the production of IgG-secreting cells is linked with the alternation of cell proliferation, because the frequencies of BrdU + were decreased in ABF-1-GFP-overexpressing cells (Fig. 1J, left panel) and increased in ABF-1 knockdown cells (Fig. 1K, left panel) . However, modulation of the levels of ABF-1 did not affect cell apoptosis (Fig. 1J, 1K, right panel) . Together, these results suggest that ABF-1 may limit the proliferation of stimulated memory B cells and the differentiation of plasma cells.
Identification of genes regulated by ABF-1
We next sought to examine the mechanisms by which ABF-1 possesses the activity to prohibit plasma cell differentiation. It is noted that the inhibitory effect of ABF-1 on the formation of Absecreting cells is associated with the higher level of BCL6, PAX5, and reduced XBP-1 mRNA, but the mRNA level of PRDM1 in ABF-1-GFP-expressing cells is not affected (Fig. 2A) , suggesting that, independently of regulating PRDM1, ectopically expressed ABF-1 may promote the expression of mature B cell or GC B genes that prohibit plasma cell differentiation.
Furthermore, the differential gene expression profiles between a human B lymphoblastoid SKW6.4 cell line (SKW) that expressed ABF-1-GFP versus those that expressed GFP alone were examined by microarray analysis. Pairwise comparison of genes differentially expressed between GFP + and ABF-1-GFP + SKW cells revealed a limited number of genes for which expression was changed by .2-fold in two of our three independent microarray experiments (Fig. 2B) . Thirty-seven genes were upregulated, and 10 genes were downregulated by ABF-1 (Supplemental Table II ). The expression of several genes, including FLI1, FCRL2, FCRL4, FCRL5, SELL, and PAX5, was validated by RT-QPCR in SKW cells (Fig. 2C) . However, in primary human memory B cell-derived culture, we only observed that FLI1 is downregulated and FCRL4 is upregulated in sorted ABF-1-GFP + cells as compared with sorted GFP + cells (Fig. 2D) . FLI1 was of particular interest because it is known to play a role in normal cell proliferation and malignant transformation (29) . Thus, downregulation of FLI1 by ABF-1 may, at least in part, explain why ectopic expression of ABF-1 limits the proliferation of stimulated memory B cells. Additionally, increased expression of FCRL4 by ABF-1 is also consistent with the notion that FCRL4 is predominantly expressed by memory B cells (30) .
ABF-1 is a direct target of Blimp-1
On day 4, at least three cellular subsets were generated in memory B cell-derived cultures, and they can be grouped according to the surface level of CD20 and CD38 (Fig. 3A) . According to a previous report (31) (Fig. 3B, left panel) . It is noted that the expression of ABF-1 mRNA is reduced in cycling plasmablasts, which is inversely correlated with the level of PRDM1 mRNA (Fig. 3B , right panel). The inverse expression profiles of ABF-1 and PRDM1 in differentiating human B cell subsets prompted us to examine if ABF-1 is directly repressed by Blimp-1. Indeed, ectopic expression of Blimp-1 by a lentiviral vector that expresses the GFP-Blimp-1 fusion protein in SKW cells reduced ABF-1 mRNA and protein levels (Fig. 3C, 3D ). We next compared the genomic sequences 3 kb upstream of the transcription start site of ABF-1 with the known Blimp-1 consensus binding sequences (32) and found five putative Blimp-1 binding sites in the 59 flanking region of ABF-1 (Fig. 3E) . A previously established stably transfected WI-L2 cell line that expresses a FLAG-tagged Blimp-1-ERD fusion protein under the control of the heavy metal-inducible metallothionein promoter was used to determine if Blimp-1 binds to ABF-1 after the addition of CdCl 2 and 4-hydroxytamoxifen (4-OHT) (10) . As shown with ChIP, Blimp-1 bound to site 4 and site 5 in the 59 flanking region of ABF-1 (Fig. 3F) . A control WI-L2-transfected cell line expressing ERD alone and a locus in the 24-kb region of ABF-1 served as negative controls. Furthermore, EMSAs demonstrated that bands representing sites 4 and 5 were shifted by Blimp-1 in nuclear extract isolated from 293T cells overexpressing Blimp-1 (Fig. 3G) . The shifted complex was abolished by addition of indicated molar excess of unlabeled oligonucleotides containing sites 4 and 5, but not by site 4 or site 5 mutant oligonucleotides. Furthermore, the shifted complex was supershifted by a Blimp-1-specific mAb, whereas a mouse IgG isotype control Ab did not supershift the complex (Fig. 3G) . Similar results were obtained with a DNA pulldown assay, which showed that recombinant tBlimp, which is a truncated form of Blimp-1 containing five zinc finger motif for DNA binding (8, 9), bound to biotinylated oligonucleotides that included site 4, site 5 or c-Myc promoter, but not to oligonucleotides containing mutated site 4 or site 5 (Fig. 3H) .
We
to +318; ABF-1-Luc), which contains the promoter region, was suppressed by Blimp-1 in a dose-dependent manner in transiently transfected 18-81 B cells (Fig. 3I) . When both site 4 and site 5 were mutated, Blimp-1-mediated repression of the ABF-1 promoter activity was blocked in the presence of lower amounts of Blimp-1 (Fig. 3I) , suggesting that both sites are involved in Blimp-1 repression. Together, these combined data indicated that Blimp-1 directly suppresses ABF-1 transcription. + GC B cells from spleen of mice received primary immunization showed increased mouse ABF-1 (Msc) mRNA levels as compared with the levels in B220 + splenic B cells of nonimmunized (naive) mice and in muscle that served as the positive control of expressing tissue; by contrast, sorted plasma cells from immunized mice had low levels of Msc mRNA (Fig. 4A) . Furthermore, Msc mRNA was induced in mouse splenic B cells stimulated in vitro with IL-21 and anti-CD40 but not with LPS or anti-IgM alone (Fig. 4B) . It is noted that treatment with IL-21 plus anti-IgM plus anti-CD40 showed a synergistic effect on the induction of Msc mRNA (Fig. 4B) . Likewise, Msc protein was induced in mouse splenic B cells 1 and 3 d after stimulation (Fig. 4C) . On day 5, Msc protein was reduced, which is linked with the robust induction of Blimp-1 protein (Fig. 4C) .
These data suggest that Msc is induced by IL-21 and CD40L signals provided by Tfh cells in GC B cells and expressed by memory B cells in mouse.
Induction of ABF-1 during primary immunization enhances the formation of Ag-specific memory B cells
To determine the function of ABF-1 in B cell immune responses in vivo, we generated TG mice that expressed ABF-1 in B cells in an inducible manner to avoid the potential effect of ABF-1 on the function of E2A during early B cell development. cDNA of ABF-1 was fused to estrogen receptor (ER) cDNA, and its transcription was controlled by a B cell-specific promoter, pEmV H , so that the function of the ABF-1-ER fusion protein in B cells could be induced via i.p. injection with 4-OHT. We obtained two mouse lines (lines 6 and 24) that expressed ABF-1-ER in splenic B cells (Fig. 5A, 5B ), but the experiments were conducted in the line that expressed higher levels of ABF-1-ER, line 24, unless otherwise specified. B cell development and Ab responses following immunization were comparable in littermate control WT and TG mice (Supplemental Fig. 1A-C) . After receiving several i.p. injections with 4-OHT (Fig. 5C ), a portion of ABF-1-ER was translocated into the nucleus of splenic B cells of TG mice (Fig. 5D) , as shown by the presence of ABF-1-ER in the nuclear fraction with enriched expression of histone deacetylase. We thus referred to the TG mice that received 4-OHT injections as ITG mice in the following experiments.
We next assessed the generation of GC B cells, Ag-specific memory B cells, and plasma cells after challenge with NP-KLH in ITG mice. Fig. 5E shows that ITG mice elicited more B220 + GL7 + CD38 2 GC B cells than did WT mice. Accordingly, ITG mice also developed a greater number of GCs because more PNA + B220 + GC B cells were detected in the spleen of ITG mice 2 wk after immunization compared with those in the spleen of WT mice (Fig. 5F ). Furthermore, elevated frequency and numbers of ) were present in the spleen of ITG mice 2 wk after immunization when compared with those of WT mice (Fig. 5G) . These data suggested that induction of ABF-1 during thymus-dependent immune response may promote the formation of Ag-specific GC B and memory B cells. Similar results were found in another ITG line (line 6) that expressed lower levels of inducible ABF-1-ER (Supplemental Fig. 1D) .
Interestingly, although there were more GC B cells in ITG mice, the frequency of BrdU + proliferating cells in the B220 + CD38 2 GL7 + GC B cell gate was lower in the spleen of ITG mice than of WT mice, even though the frequency of BrdU + in non-B cells (B220 2 ) isolated from splenocytes of WT and ITG mice was comparable (Fig. 5H) . These contradictory data showing increased numbers but reduced proliferation of GC B cells in ITG mice suggest that ABF-1 may have additional functions that ultimately maintain GC B cells.
Together, by using an inducible ABF-1 TG model, we demonstrated that induced ABF-1 promotes the formation of GC and memory B cells after immunization with NP-KLH.
Induction of ABF-1 during primary and secondary immunization prevents plasma cell formation in mouse
With regard to the generation of plasma cells, we found that the number of plasma cells that secreted either NP 52 -specific IgG or NP 4 -specific IgG in the spleen of NP-KLH-immunized ITG mice was compromised as compared with those of WT mice 14 d after immunization (Fig. 6A) . Congruently, the total NP 52 -specific IgG titer in sera from ITG mice was less than that in WT mice 14 and 21 d after immunization (Fig. 6B) . Additionally, compared with WT mice, the serum levels of high-affinity NP 4 -specific IgG in ITG mice were reduced 7 and 14 d after immunization (Fig. 6C) , but NP-specific IgM levels in sera did not change significantly in ITG mice (Fig. 6D) . However, the ratio of NP 4 /NP 52 was comparable between WT and ITG mice (Fig. 6E) .
Given that ectopic expression of ABF-1 inhibited the generation of human plasma cells derived from memory B cells in vitro, we assessed whether induction of ABF-1 activity in TG mice during secondary immunization (2ITG) could recapture the decreased generation of plasma cells (Fig. 7A) . Although the frequency of GC B cells was comparable in WT and TG mice before Ag recall, the frequency of GC B cells was increased in 2ITG mice (Fig. 7B) , which is similar to the effect of ABF-1 on enhancing GC B cell formation in primary immunization. The numbers of total NP 52 -specific IgG-producing cells and NP 4 -specific IgGsecreting cells were significantly reduced in the spleen of 2ITG mice 7 d after Ag recall (Fig. 7C) . Furthermore, the frequency of emerging plasma cell precursors or preplasma memory B cells, defined as NP + CD79b + B220 2 CD138 2 (3, 33), in the spleen of 2ITG mice 5 d after Ag recall was consistently reduced (Fig. 7D,  7E ) as compared with those in WT mice, even though the fre- The Journal of Immunologyquency of memory B and plasma cell precursors was comparable in WT and TG mice before secondary immunization (Fig. 7E) . These data supported our results from human plasma cell differentiation in culture showing that overexpression of ABF-1 in stimulated memory B cells reduced the formation of plasma cells. Lastly, we wish to examine if ITG mice indeed developed more memory B cells than WT mice did after immunization. We adoptively transferred plasma cell-depleted splenocytes isolated from either WT or ITG immunized mice (CD45.2) to recipient mice (CD45.1), followed by boosting of recipient mice with NP-KLH (Fig. 7F) . Results in Fig. 7G showed that mice received plasma cell-depleted splenocytes from ITG mice produced more NP 52 -specific IgG than mice received cells from WT mice. Consistently, at day 6 after adoptive transfer, mice (CD45.1) received plasma cell-depleted splenocytes from ITG mice had more B220 2 CD138 + CD45.2 + plasma cells in bone marrow than mice received WT cells (Fig. 7G) , supporting the notion that ITG mice generated more memory B cells after immunization.
Discussion
In this study, we provide evidence showing that ABF-1 is directly suppressed by Blimp-1 based on several of findings: 1) ectopic expression of Blimp-1 reduced endogenous ABF-1 mRNA and protein levels; 2) Blimp-1 bound to two sites in the 59 flanking region of ABF-1 as shown by the ChIP assay, EMSA, and DNA pulldown assay; and 3) ABF-1 promoter activity was repressed by Blimp-1 in a site-and dose-dependent manner in cotransfected cells, as shown by the luciferase reporter assay. A minimal ABF-1 promoter was previously reported to be ∼182 bp upstream of the transcription start site (34) . We found two elements located in the 59 flanking region of ABF-1 that were responsive to Blimp-1 expression. One was located at 22850 to 22841 (site 5), and the other was at 22246 to 22235 (site 4). Both are further upstream of the previously reported ABF-1 minimal promoter. In fact, two other sites that are near 22118 to 22073 (site 2 and site 3) also contained potential Blimp-1 binding sequences. Using the ChIP assay would not be practical for determining the precise element(s) in the cluster of sites 2-4 that were directly bound by Blimp-1. We reasoned that site 4 in this cluster was the predominant Blimp-1 binding site because the activity of a luciferase reporter fused with the ABF-1 promoter carrying mutations at both sites 2 and 3 was still suppressed by Blimp-1 (Supplemental Fig. 2A) . However, as ABF-1 regulation and its B cell-restricted control elements have not been fully characterized, it is possible that Blimp-1 regulates ABF-1 through additional sites.
A role for ABF-1 in blocking the B cell phenotype in Hodgkin lymphoma has been reported (16) . In this study, we showed a previously unknown function for ABF-1 in normal B cells. ABF-1 was shown to be induced following treatment of peripheral human B cells with Staphylococcus aureus Cowan 1 (SAC) (14) . In this study, in human memory B cell culture, ABF-1 mRNA levels were increased in the initial phase of memory B cells in culture when stimulated with IL-21 and anti-CD40, which mimics Tfh cell contact (1) . In mouse splenic B cell culture, Msc mRNA and protein were as well induced by IL-21 and anti-CD40. The induction of Msc mRNA was synergistically induced by the combined treatment with IL-21, anti-CD40 and anti-IgM despite that anti-IgM treatment alone decreased Msc mRNA. Additionally, inhibition of NF-kB, but not p38 MAPK and ERK, signaling blocks the induction of Msc mRNA by the treatment with IL-21, anti-CD40, and anti-IgM (Supplemental Fig. 2B ). The reasons why SAC, a mitogen capable of triggering human B cell proliferation and activation through cross-linking of surface Ig (35) , induced ABF-1 in human B cells, but anti-IgM reduced Msc in mouse B cells are still unknown. It could be that SAC and anti-IgM affect different subsets of B cells (36) . Additionally, the precise signaling pathways/molecules leading to the induction of ABF-1 (Msc) require further identification. Nevertheless, our data suggest that TLR-mediated signal may not be a potent inducer for the expression of Msc because LPS treatment in fact reduced Msc mRNA in mouse splenic B cells. How ABF-1/Msc becomes preferentially expressed in memory B cells remains unknown. It is possible that during the GC reaction in vivo, some B cells that acquired Tfh-mediated signals for higher ABF-1/Msc expression commit to becoming memory B cells.
In this study, we provide evidence showing that ABF-1 prevented the formation of IgG-secreting plasma cells by both the primary human memory B cell culture and the TG mouse model. We reasoned that reduced IgG production may result from a negative role for ABF-1 in the differentiation of memory B cells into IgGsecreting plasma cells. High-affinity GC B cells are selected to form plasma cells (37) . However, the NP 4 /NP 52 ratio was comparable between WT and ITG mice after immunization with NP-KLH. Thus, we suspect that ABF-1 is involved in the machinery that controls the maintenance of GC B toward memory B cells, thereby prohibiting the differentiation of Ab-secreting cells. IgMbearing memory B cells can be derived from the early stage of GC reaction (38) or independently of GCs (39) . Although ABF-1 blocked the formation of human IgM-secreting cells in some culture, ITG mice produced normal amounts of Ag-specific IgM in primary immunization. Using our approach, we could not exclude the possibility that ABF-1 activity was not effectively induced by 4-OHT injections prior to the formation of IgM-secreting cells or IgM-bearing memory B cells, as both types of cells were generated early during primary immune responses. Although the expression levels of ABF-1 are low in naive B cells in both human and mouse, it is also plausible that ABF-1 negatively regulates naive B cell differentiation into IgM-secreting plasma cells. Therefore, the role of ABF-1 in the production of IgM awaits to be clarified.
What are the molecular mechanisms underlying ABF-1 suppression of plasma cell differentiation? ABF-1 appears to increase PAX5 and BCL6 transcription, likely through an indirect mechanism because ABF-1 is a transcriptional repressor (14) . The ABF-1-mediated reduction of XBP-1 may, at least in part, result from increased PAX5 expression, because XBP-1, the gene required for Ab secretion in plasma cell differentiation (8) , is suppressed by PAX5 (40) . PAX5 is essential for B cell lineage commitment and maintenance of B cell identity (41) . Downregulation of PAX5 during plasma differentiation is necessary and sufficient for plasma cell differentiation (9, 42, 43) . As ABF-1 upregulates PAX5, it is conceivable that ABF-1 may be suppressed to allow plasma cell formation. Furthermore, ABF-1 elevated the expression of BCL6, the important regulator for GC formation (44) , which is reconciled by our results from NP-KLH-immunized ITG mice showing that ABF-1 promotes the generation of GC B cells. Interestingly, our microarray data revealed that several FCRLs were upregulated by ABF-1. Among them, FCRL2 and FCRL4 are predominantly expressed by memory B cells (30) , supporting again the notion that ABF-1 expression is relevant to memory B cell fate. Although FCRL4 has been shown to negatively regulate BCR-mediated activation (45) , its role in memory B cells awaited future studies. Another target obtained from our microarray data is FLI1, which has been implicated in accelerating cell proliferation (29) . Its overexpression in mice leads to B cell hyperplasia and a spontaneous systemic lupus erythematosus-like disease (46, 47) . More importantly, the proliferation of B cells from Fli1-deficient mice is impaired (48) . These combined findings suggested that the diminished cell proliferation resulting from ec- topic expression of ABF-1 in human memory B cells may be partly due to reduced FLI1 expression. Furthermore, ABF-1-mediated suppression of FLI1 may at least partly explain why memory B cells manifest cell-cycle arrest (49) , although it requires further experiments to test this hypothesis.
In summary, in this study, we propose a gene regulatory pathway for Blimp-1 and ABF-1 during memory B cells versus plasma cell fate commitment. Tfh-primed GC B cells that acquire the expression of ABF-1 may differentiate toward the memory B cell fate, whereas Blimp-1-expressing cells may bias the formation of plasma cells that in turn show the reduced expression of ABF-1. During the differentiation of plasma cells from memory B cells, the induced Blimp-1 suppresses ABF-1, leading to derepression of ABF-1 downstream genes, such as FLI1 that is involved in cell proliferation. As a consequence, it may permit further rounds of proliferation for allowing the production of Ab-secreting cells. 
SELL F TGGACAATGCTCTGTTGTGATTTC
SELL R TCCAGCAGTCGGTTCCATG
FLI1 F GGCACAAACGATCAGTAAGAATACAG
FLI1 R GAATTGCCACAGCTGGATCTG
FCRL2 F CTGCCACTAATGAACCCAGAGG
FCRL2 R GGTTGGGCTTGAATAGGTGAACT
FCRL4 F CCCTCGCTACAGATCCATGTG
FCRL4 R TCTCCAGGAGCACCCCAG
FCRL5 F GTTCCCGTGTCTCATCCTGTC
